Challenges, successes and hopes in the development of novel TB therapeutics

Future Medicinal Chemistry

Volumn 1, Issue 4, 2009, Pages 749-756

  Sacks, Leonard V ^a   Behrman, Rachel E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 5 NITROIMIDAZOLE DERIVATIVE; DIARYLQUINOLINE DERIVATIVE; ETHAMBUTOL; ETHYLENEDIAMINE; LL 3858; METRONIDAZOLE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITRODIHYDRO INIDAZOOXAZOLE; NITROIMIDAZOPYRAN; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TINIDAZOLE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FUNDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; DRUG RESISTANCE, BACTERIAL; HIGH-THROUGHPUT SCREENING ASSAYS; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 77953438419     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.53     Document Type: Short Survey

References (44)

1. Frieden FR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 362, 887-899 (2003).
2. WHO. Global Tuberculosis control 2008, surveillance, planning, financing. WHO report 2008 WHO/HTM/TB/2008.393.
3. Centers for Disease Control and Prevention: trends in tuberculosis incidence. United States 2006. MMWR 56, 245-250 (2007).
4. WHO. Anti-tuberculosis drug resistance in the world. Fourth global report WHO/ HTM/TB/2008.394.
5. Ghandi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
6. Manca C, Tsenova L, Barry CE et al. Mycobacterium tuberculosis CDC 1551 induces a more vigorous host response in vivo and in vitro but is not more virulent than other clinical isolates. J. Immunol. 162, 6740-6746 (1999).
7. Brock T, Madigan M. Biology of Microorganisms (6th Edition). Prentice Hall, NJ, USA (1991).
8. Archibald FS, DeVoe IW. Iron in Neisseria meningitides: minimum requirements, effects of limitation, and characteristics of uptake. J. Bacteriol. 136, 35-48 (1978).
9. Mazzola GJ, Mortensen JE, Miller LA, Poupard JA. The growth and survivability of Streptococcus pneumoniae clinical isolates subjected to various environmental conditions. Diagn. Microbiol. Infect. Dis. 45, 153-164 (2003).
10. Tatini SR, Stein SA, Soo HM. Influence of protein supplements on growth of Staphylococcus aureus and production of enterotoxins. J. Food Sci. 41, 133-135 (1976).
11. Jain SK, Lamichhane G, Nimmagadda S, Pomper MG, Bishai WR. Antibiotic treatment of tuberculosis: old problems, new solutions. Microbe 3, 285-292 (2008)
12. Brennan PJ. Structure, function and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis 83, 91-97 (2003).
13. Kunz R, Gundermann KC. The survival of Mycobacterium tuberculosis on surfaces at different relative humidities. Arch. Hyg. Bakteriol. 176, 105-115 (1982).
14. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis units 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3, S231-S279 (1999).
15. Miglori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercule bacillus: the new XDR-TB threat. Is science enough to tackle the epidemic? Eur. Respir. J. 29, 423-427 (2007).
16. Combs DL, O'Brien RJ, Ceiter LJ. USPS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and acceptability. Ann. Intern. Med. 112, 397-406 (1990).
17. Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169, 1103-1109 (2004).
18. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of communitybased directly observed therapy for tuberculosis. JAMA 274, 945-951 (1995).
19. Ipuge YA, Rieder HL, Enarson DA. Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania. Lancet 346, 657-660 (1995).
20. Yew WW, Wong PC, Lee J, Chau CH. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin. Infect. Dis. 17, 288-289 (1993).
21. Vernon A, Buurman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once weekly rifapentine and isoniazid. Lancet 353, 1843-1847 (1999).
22. Glickman SW, Rasiel EB, Dukes-Hamilton C, Kubataev A, Schulman KA. A portfolio model of drug development for tuberculosis. Science 311, 1246-1247 (2006).
23. Check E. After decades of drought, new drug possibilities flood TB pipeline. Nat. Med. 13 266 (2007)
24. Raman K, Rajagopalan P, Chandra N. Flux balance analysis of mycolic acid pathway: targets for anti-tubercular drugs. PLoS Comput. Biol. 1, 349-358 (2005).
25. Wilson M, DeRis J, Kristensen HH et al. Exploring drug-induced alteration in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl Acad. Sci. USA 96, 12833-12838 (1999).
26. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/ clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26, 874-877 (1998).
27. Fortun J, Martin-Davila P, Navas E et al. Linezolid for the treatment of multidrugresistant tuberculosis. J. Antimicrob. Chemother. 56, 180-185 (2005).
28. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054-2058 (1994).
29. Collins LA, Franzblau SG. Microplate alamar blue assay versus bactec 460 system for high throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 41, 1004-1009 (1997).
30. Balganesh TS, Balasubramanian V, Kumar SA. Drug discovery for tuberculosis: bottlenecks and path forward. Curr. Sci. 86, 167-176 (2004).
31. Barry CE, Duncan K. Tuberculosis - strategies towards anti-infectives for a chronic disease. Drug Discov. Today 1, 491-496 (2004).
32. Ashtekar DR, Costa-Perira R, Nagrajan K. Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37, 183-186 (1993).
33. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, 2131-2143 (2006).
34. Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966 (2000).
35. Ma Z. Overview of the global TB pipleline (Abstract). Int. J. Tuberc. Lung Dis. 12, S13 (2008).
36. Diacon A, Dawson R, Venter A et al. Update on PA-824. Int. J. Tuberc. Lung Dis. 12, S14 (2008).
37. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52, 2831-2835 (2008).
38. Diacon AH, Pym A, Grobusch M et al. Interim analysis of a double-blind, placebo-controlled study with TMC207 in patients with multi-drug resistant (MDR) Tuberculosis, (Abstract). Presented at: 48th Annual ICAAC. Washington DC, USA. 25-28 October 2008.
39. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56, 968-974 (2005).
40. Horwith G, Einck L, Protopopova M, Nacy C. Phase 1 safety and pharmacokinetics of SQ109, a new diamine anti-tuberculosis drug (meeting Abstract 1128). Am. J. Infect. Dis. (2007).
41. Arora SK, Anuradha K, Avhad AJ. Phase 1 clinical trial of LL-3858 (Sudoterb), a potential candidate for the treatment of MDR tuberculosis. Int. J. Tuberc. Lung Dis. 12, S319 (2008).
42. Wayne LG, Sohaskey CD. Non-replicating persistence of Mycobacteruim tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001).
43. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717-731 (2002).
44. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacteruim tuberculosis. Antimicrob. Agents Chemother. 47, 653-657 (2003).